Breaking News Instant updates and real-time market news.

CANO

Cano Health

$6.53 /

+1.975 (+43.36%)

06:23
03/10/22
03/10
06:23
03/10/22
06:23

Citi sees potential for Cano Health buyout near $12 per share

Citi analyst Jason Cassorla keeps a Buy rating on Cano Health with a $12 price target after Third Point proposed that the company should commence a review of strategic alternatives, including an outright sale. The analyst sees potential for a possible takeout near his price target of $12 with a "plethora of potential buyers." The stock is down over 70% since the highs post the special purpose acquisition company merger, which is a function of multiple compression for peers that are tethered to Medicare Advantage-focused, value-based primary care, Cassorla tells investors in a research note. He believes private equity could have interest and also sees strategic fit potential for Cano.

OTHER BREAKING NEWS FROM THE FLY

General news
Market Update: » 02:50
12/01/22
12/01
02:50
12/01/22
02:50
$ECON

Economic Data

/

+

Market Update: Wall…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
China's Caixin manufacturing PMI inched up 0.2 ticks to 49.4 in November » 23:10
11/30/22
11/30
23:10
11/30/22
23:10
$ECON

Economic Data

/

+

China's Caixin…

China's Caixin manufacturing PMI inched up 0.2 ticks to 49.4 in November after rising 1.1 points to 49.2 in October. However, this is a fourth straight month in contraction. And it mirrors the official PMI gauge declined -1.2 points to 48.0 in November with weakness in both output and demand (and the employment metric remained in contraction for a 20th straight month. The continued zero-covid restrictions and a slowdown in overseas demand continue to weigh on China's economy. Reflecting the latter slippage, exports fell -0.3% y/y in October, the first contraction since May 2020. The report indicated that the contraction in the employment component was the largest since February 2020. contracted for the first time

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Periodicals
EPA to propose boost in biofuel quotas, Reuters reports » 20:58
11/30/22
11/30
20:58
11/30/22
20:58
ADM

Archer Daniels

$97.49 /

+1.05 (+1.09%)

, ALTO

Alto Ingredients

$3.49 /

+0.055 (+1.60%)

, BG

Bunge

$104.84 /

+0.765 (+0.74%)

, DAR

Darling Ingredients

$71.83 /

+1.94 (+2.78%)

, GPRE

Green Plains

$34.55 /

+1.905 (+5.84%)

, PBF

PBF Energy

$39.80 /

-1.72 (-4.14%)

, PSX

Phillips 66

$108.39 /

-0.61 (-0.56%)

, MPC

Marathon Petroleum

$121.79 /

-1.62 (-1.31%)

, VLO

Valero

$133.72 /

-1.48 (-1.09%)

The U.S. Environmental…

The U.S. Environmental Protection Agency will propose increases in the quotas of ethanol and other biofuels that refiners must blend into their fuel over the next three years, two sources familiar with the matter told Reuters' Stephanie Kelly and Jarrett Renshaw. The agency's proposal expected later this week will call for overall blending mandates of 20.82B gallons in 2023, 21.87B gallons in 2024 and 22.68B gallons in 2025, the report said. Reference Link

ShowHide Related Items >><<
VLO Valero
$133.72 /

-1.48 (-1.09%)

PSX Phillips 66
$108.39 /

-0.61 (-0.56%)

PBF PBF Energy
$39.80 /

-1.72 (-4.14%)

MPC Marathon Petroleum
$121.79 /

-1.62 (-1.31%)

GPRE Green Plains
$34.55 /

+1.905 (+5.84%)

DAR Darling Ingredients
$71.83 /

+1.94 (+2.78%)

BG Bunge
$104.84 /

+0.765 (+0.74%)

ALTO Alto Ingredients
$3.49 /

+0.055 (+1.60%)

ADM Archer Daniels
$97.49 /

+1.05 (+1.09%)

ADM Archer Daniels
$97.49 /

+1.05 (+1.09%)

10/26/22 Baird
Archer Daniels price target raised to $98 from $94 at Baird
10/24/22 BofA
Green Plains price target lowered to $35 from $43 at BofA
10/24/22 BofA
Archer Daniels price target lowered to $100 from $104 at BofA
10/04/22 Lake Street
Benson Hill initiated with a Buy at Lake Street
ALTO Alto Ingredients
$3.49 /

+0.055 (+1.60%)

BG Bunge
$104.84 /

+0.765 (+0.74%)

10/24/22 BofA
Bunge price target lowered to $130 from $138 at BofA
08/12/22 Wolfe Research
Wolfe Research starts Bunge at Outperform on upside to guided growth
DAR Darling Ingredients
$71.83 /

+1.94 (+2.78%)

10/19/22 Scotiabank
Darling Ingredients selloff on deal a buying opportunity, says Scotiabank
10/19/22 Jefferies
Darling Ingredients initiated with a Buy at Jefferies
09/12/22 Stifel
Darling Ingredients initiated with a Buy at Stifel
09/08/22 Scotiabank
Darling Ingredients initiated with an Outperform at Scotiabank
GPRE Green Plains
$34.55 /

+1.905 (+5.84%)

10/24/22 BMO Capital
Green Plains downgraded to Market Perform from Outperform at BMO Capital
10/07/22 Truist
Green Plains price target lowered to $48 from $55 at Truist
PBF PBF Energy
$39.80 /

-1.72 (-4.14%)

11/09/22 Piper Sandler
PBF Energy price target raised to $69 from $53 at Piper Sandler
10/06/22 Piper Sandler
PBF Energy price target raised to $53 from $49 at Piper Sandler
09/23/22 Piper Sandler
PBF Energy price target raised to $49 from $45 at Piper Sandler
09/21/22 JPMorgan
PBF Energy upgraded to Overweight from Neutral at JPMorgan
PSX Phillips 66
$108.39 /

-0.61 (-0.56%)

11/11/22 Wells Fargo
Wells Fargo downgrades DCP Midstream on Phillips 66 offer
11/09/22 Piper Sandler
Phillips 66 price target raised to $155 from $116 at Piper Sandler
11/03/22 Wells Fargo
Phillips 66 price target raised to $134 from $123 at Wells Fargo
11/02/22 JPMorgan
DCP Midstream downgraded to Neutral from Overweight at JPMorgan
MPC Marathon Petroleum
$121.79 /

-1.62 (-1.31%)

11/09/22 Piper Sandler
Marathon Petroleum price target raised to $153 from $111 at Piper Sandler
11/03/22 Wells Fargo
Marathon Petroleum price target raised to $131 from $116 at Wells Fargo
10/19/22 Jefferies
Marathon Petroleum initiated with a Hold at Jefferies
10/10/22 Barclays
Marathon Petroleum price target raised to $126 from $112 at Barclays
VLO Valero
$133.72 /

-1.48 (-1.09%)

11/09/22 Piper Sandler
Valero price target raised to $177 from $147 at Piper Sandler
10/26/22 Wells Fargo
Valero price target raised to $137 from $131 at Wells Fargo
10/26/22 Barclays
Valero price target raised to $138 from $134 at Barclays
10/19/22 Jefferies
Valero initiated with a Buy at Jefferies
VLO Valero
$133.72 /

-1.48 (-1.09%)

PSX Phillips 66
$108.39 /

-0.61 (-0.56%)

PBF PBF Energy
$39.80 /

-1.72 (-4.14%)

MPC Marathon Petroleum
$121.79 /

-1.62 (-1.31%)

GPRE Green Plains
$34.55 /

+1.905 (+5.84%)

DAR Darling Ingredients
$71.83 /

+1.94 (+2.78%)

BG Bunge
$104.84 /

+0.765 (+0.74%)

ALTO Alto Ingredients
$3.49 /

+0.055 (+1.60%)

ADM Archer Daniels
$97.49 /

+1.05 (+1.09%)

PSX Phillips 66
$108.39 /

-0.61 (-0.56%)

ADM Archer Daniels
$97.49 /

+1.05 (+1.09%)

PSX Phillips 66
$108.39 /

-0.61 (-0.56%)

PBF PBF Energy
$39.80 /

-1.72 (-4.14%)

DAR Darling Ingredients
$71.83 /

+1.94 (+2.78%)

BG Bunge
$104.84 /

+0.765 (+0.74%)

ADM Archer Daniels
$97.49 /

+1.05 (+1.09%)

VLO Valero
$133.72 /

-1.48 (-1.09%)

PSX Phillips 66
$108.39 /

-0.61 (-0.56%)

MPC Marathon Petroleum
$121.79 /

-1.62 (-1.31%)

ADM Archer Daniels
$97.49 /

+1.05 (+1.09%)

Recommendations
Semtech price target lowered to $45 from $60 at Piper Sandler » 20:58
11/30/22
11/30
20:58
11/30/22
20:58
SMTC

Semtech

$30.74 /

+1.42 (+4.84%)

Piper Sandler analyst…

Piper Sandler analyst Harsh Kumar lowered the firm's price target on Semtech to $45 from $60 but keeps an Overweight rating on the shares. The analyst notes that the quarter was mixed with a beat on Q3 earnings and a miss on Q4, though he also sees the main takeaway from the earnings call coming from commentary suggesting "business stabilization" in several end markets including China. Kumar adds that Q1 of FY24 should mark the bottom in revenues, with traction coming in the July quarter and further into the second half of 2023.

ShowHide Related Items >><<
SMTC Semtech
$30.74 /

+1.42 (+4.84%)

SMTC Semtech
$30.74 /

+1.42 (+4.84%)

11/22/22 Stifel
Semtech price target lowered to $40 from $45 at Stifel
10/04/22 B. Riley
Semtech price target lowered to $34 from $53 at B. Riley
09/01/22 B. Riley
Semtech price target lowered to $53 from $63 at B. Riley
09/01/22 Benchmark
Semtech positions should be added to on weakness, says Benchmark
SMTC Semtech
$30.74 /

+1.42 (+4.84%)

SMTC Semtech
$30.74 /

+1.42 (+4.84%)

SMTC Semtech
$30.74 /

+1.42 (+4.84%)

Syndicate
Aura Biosciences 6.7M share Spot Secondary priced at $12.00 » 20:51
11/30/22
11/30
20:51
11/30/22
20:51
AURA

Aura Biosciences

$14.09 /

+0.255 (+1.84%)

SVB Securities, Cowen and…

SVB Securities, Cowen and Evercore ISI are acting as joint book running managers for the offering. The deal priced at low end of $12.00-$12.50 range.

ShowHide Related Items >><<
AURA Aura Biosciences
$14.09 /

+0.255 (+1.84%)

AURA Aura Biosciences
$14.09 /

+0.255 (+1.84%)

07/19/22 JMP Securities
Aura Biosciences initiated with an Outperform at JMP Securities
AURA Aura Biosciences
$14.09 /

+0.255 (+1.84%)

  • 01
    Dec
AURA Aura Biosciences
$14.09 /

+0.255 (+1.84%)

Hot Stocks
Iris Acquisition to combine with Liminatus Pharma » 20:49
11/30/22
11/30
20:49
11/30/22
20:49
IRAA

Iris Acquisition

$10.02 /

+0.005 (+0.05%)

Liminatus Pharma and Iris…

Liminatus Pharma and Iris Acquisition Corp "announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed "Liminatus Pharma, Inc.". The combined company's common stock is expected to be listed on the Nasdaq Capital Market. The transaction funding includes commitments for a $15M common stock PIPE financing and a $25M convertible note financing to further support Liminatus' business growth strategy. The business combination implies a pro forma enterprise value of the combined company of approximately $334 million. The combined company is expected to receive gross cash proceeds of up to $316M, comprising the $276 million held in Iris' trust account and a concurrent, committed $15 million equity PIPE financing of common stock issued at $10.00 per share and $25M convertible note financing with an initial conversion rate of $11.50 per share of common stock, subject to future adjustments based upon the price of Iris' publicly traded common stock. The combined company will bear deferred underwriting commissions and transaction expenses out of the gross proceeds."

Hot Stocks
Arco Platform announces receipt of going private proposal » 20:47
11/30/22
11/30
20:47
11/30/22
20:47
ARCE

Arco Platform

$9.02 /

+0.6 (+7.13%)

Arco Platform…

Arco Platform "announced that its board of directors has received a preliminary non-binding proposal dated November 30, 2022 from General Atlantic L.P. and Dragoneer Investment Group, LLC to acquire all of the outstanding Class A common shares of the Company that are not held by such parties or Oto Brasil de Sa Cavalcante and Ari de Sa Cavalcante Neto or their respective affiliates. The proposal states that the Founders support the Proposed Transaction and will roll over 100% of their Class A common shares and Class B common shares in the Proposed Transaction, and that after the closing of the Proposed Transaction, the Founders will maintain the same economic and voting interest in the Company as they currently have. The purchase price proposed by General Atlantic and Dragoneer for each Class A common share is $11.00 in cash, which represents an approximately 22% premium over today's closing price of $9.04 per Class A common share."

ShowHide Related Items >><<
ARCE Arco Platform
$9.02 /

+0.6 (+7.13%)

ARCE Arco Platform
$9.02 /

+0.6 (+7.13%)

10/26/22 Goldman Sachs
Arco Platform downgraded to Neutral from Buy at Goldman Sachs
10/21/22 Morgan Stanley
Arco Platform price target lowered to $17 from $23.50 at Morgan Stanley
10/21/22 Morgan Stanley
Vasta Platform downgraded at Morgan Stanley on relative valuation to Arco
08/30/22 JPMorgan
Arco Platform upgraded to Overweight from Neutral at JPMorgan
ARCE Arco Platform
$9.02 /

+0.6 (+7.13%)

Periodicals
HP Enterprise expressed takeover interest in Nutanix, Bloomberg says » 20:38
11/30/22
11/30
20:38
11/30/22
20:38
NTNX

Nutanix

$28.23 /

+1.095 (+4.04%)

, HPE

HP Enterprise

$16.79 /

+1.325 (+8.57%)

HP Enterprise (HPE) has…

HP Enterprise (HPE) has held talks with Nutanix (NTNX) in recent months about a potential takeover, Bloomberg's Liana Baker, Katie Roof, and Scott Deveau report, citing people familiar with the matter. The report notes that the talks have been "on and off" and may not lead to a deal as another buyer may emerge or Nutanix may remain independent.

ShowHide Related Items >><<
NTNX Nutanix
$28.23 /

+1.095 (+4.04%)

HPE HP Enterprise
$16.79 /

+1.325 (+8.57%)

NTNX Nutanix
$28.23 /

+1.095 (+4.04%)

10/24/22 KeyBanc
Nutanix price target raised to $33 from $26 at KeyBanc
10/17/22 Needham
Nutanix price target raised to $31 from $25 at Needham
10/11/22 Cleveland Research
Nutanix upgraded to Buy from Neutral at Cleveland Research
09/01/22 Needham
Nutanix price target raised to $25 from $20 at Needham
HPE HP Enterprise
$16.79 /

+1.325 (+8.57%)

11/30/22 Susquehanna
HP Enterprise price target raised to $16 from $15 at Susquehanna
11/30/22 Deutsche Bank
HP Enterprise price target raised to $16 from $15 at Deutsche Bank
11/30/22 Morgan Stanley
HP Enterprise price target raised to $13 from $12 at Morgan Stanley
11/30/22 Citi
HP Enterprise price target raised to $13 from $11.50 at Citi
NTNX Nutanix
$28.23 /

+1.095 (+4.04%)

HPE HP Enterprise
$16.79 /

+1.325 (+8.57%)

NTNX Nutanix
$28.23 /

+1.095 (+4.04%)

NTNX Nutanix
$28.23 /

+1.095 (+4.04%)

HPE HP Enterprise
$16.79 /

+1.325 (+8.57%)

NTNX Nutanix
$28.23 /

+1.095 (+4.04%)

HPE HP Enterprise
$16.79 /

+1.325 (+8.57%)

Earnings
Notable companies reporting before tomorrow's open » 20:25
11/30/22
11/30
20:25
11/30/22
20:25
DG

Dollar General

$255.62 /

+2.785 (+1.10%)

, KR

Kroger

$49.20 /

-0.135 (-0.27%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Dollar General (DG), consensus $2.53... Kroger (KR), consensus 82c.

ShowHide Related Items >><<
KR Kroger
$49.20 /

-0.135 (-0.27%)

DG Dollar General
$255.62 /

+2.785 (+1.10%)

DG Dollar General
$255.62 /

+2.785 (+1.10%)

11/29/22 Deutsche Bank
Dollar General price target raised to $293 from $265 at Deutsche Bank
11/28/22 Oppenheimer
Dollar General price target raised to $285 from $275 at Oppenheimer
11/16/22 Evercore ISI
Walmart price target raised to $140 from $135 at Evercore ISI
11/07/22 Morgan Stanley
Amazon outlook 'a warning shot for discretionary retailers,' says Morgan Stanley
KR Kroger
$49.20 /

-0.135 (-0.27%)

11/29/22 Deutsche Bank
Kroger price target raised to $56 from $54 at Deutsche Bank
11/09/22 Evercore ISI
Kroger upgraded to Outperform from In Line at Evercore ISI
10/21/22 BMO Capital
Albertsons upgraded to Market Perform from Underperform at BMO Capital
KR Kroger
$49.20 /

-0.135 (-0.27%)

DG Dollar General
$255.62 /

+2.785 (+1.10%)

KR Kroger
$49.20 /

-0.135 (-0.27%)

DG Dollar General
$255.62 /

+2.785 (+1.10%)

KR Kroger
$49.20 /

-0.135 (-0.27%)

DG Dollar General
$255.62 /

+2.785 (+1.10%)

KR Kroger
$49.20 /

-0.135 (-0.27%)

DG Dollar General
$255.62 /

+2.785 (+1.10%)

Hot Stocks
Cathie Wood's ARK Investment bought 39.2K shares of Crowdstrike today  20:03
11/30/22
11/30
20:03
11/30/22
20:03
CRWD

Crowdstrike

$117.56 /

-20.62 (-14.92%)

 
ShowHide Related Items >><<
CRWD Crowdstrike
$117.56 /

-20.62 (-14.92%)

CRWD Crowdstrike
$117.56 /

-20.62 (-14.92%)

11/30/22 Truist
Crowdstrike price target lowered to $200 from $275 at Truist
11/30/22 RBC Capital
Crowdstrike price target lowered to $165 from $200 at RBC Capital
11/30/22 Needham
Crowdstrike price target lowered to $165 from $225 at Needham
11/30/22 DA Davidson
Crowdstrike price target lowered to $145 from $235 at DA Davidson
CRWD Crowdstrike
$117.56 /

-20.62 (-14.92%)

CRWD Crowdstrike
$117.56 /

-20.62 (-14.92%)

CRWD Crowdstrike
$117.56 /

-20.62 (-14.92%)

CRWD Crowdstrike
$117.56 /

-20.62 (-14.92%)

Hot Stocks
Onica Rackspace Technology achieves Service Delivery designation for AWS Glue » 19:11
11/30/22
11/30
19:11
11/30/22
19:11
RXT

Rackspace Technology

$4.89 /

+0.335 (+7.36%)

, AMZN

Amazon.com

$96.50 /

+4.1 (+4.44%)

Rackspace Technology…

Rackspace Technology "announced that Onica by Rackspace Technology, the cloud services-focused business group, announced today that it has achieved the Amazon Web Service Service Delivery designation for AWS Glue. The AWS Glue Service Delivery designation recognizes that Onica by Rackspace Technology has proven success in helping customers discover consulting partners who have the expertise to deliver AWS Glue for data integration, pipeline, and catalogue use cases. AWS Partners with this designation makes it easy for customers to discover, prepare, and combine data for analytics, machine learning, and application development. AWS Glue provides all the capabilities needed for data integration such that customers can start analyzing their data and putting it to use in minutes instead of months. To receive this designation, Amazon Partner Network members must possess deep AWS experience and deliver solutions seamlessly on AWS."

ShowHide Related Items >><<
RXT Rackspace Technology
$4.89 /

+0.335 (+7.36%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

RXT Rackspace Technology
$4.89 /

+0.335 (+7.36%)

11/21/22 Citi
Rackspace Technology price target lowered to $5 from $7 at Citi
11/10/22 Deutsche Bank
Rackspace Technology price target lowered to $5 from $6 at Deutsche Bank
10/11/22 Evercore ISI
Rackspace Technology downgraded to In Line at Evercore ISI on 2023 risks
10/11/22 Evercore ISI
Rackspace Technology downgraded to In Line from Outperform at Evercore ISI
AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

11/30/22 JMP Securities
JMP Securities encouraged by Amazon.com's focus on innovation
11/29/22 UBS
Affirm initiated with a Neutral at UBS
11/22/22 Piper Sandler
Amazon.com price target lowered to $119 from $125 at Piper Sandler
11/21/22 JPMorgan
JPMorgan more cautious on online holiday sales, Amazon still top idea
RXT Rackspace Technology
$4.89 /

+0.335 (+7.36%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

RXT Rackspace Technology
$4.89 /

+0.335 (+7.36%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

On The Fly
Fly Intel: After-Hours Movers » 19:01
11/30/22
11/30
19:01
11/30/22
19:01
OKTA

Okta

$53.31 /

+2.06 (+4.02%)

, PVH

PVH Corp.

$67.30 /

+2.45 (+3.78%)

, FIVE

Five Below

$160.98 /

+3.91 (+2.49%)

, SPLK

Splunk

$77.63 /

+1.685 (+2.22%)

, SNPS

Synopsys

$339.57 /

+16.07 (+4.97%)

, PSTG

Pure Storage

$29.19 /

-0.3 (-1.02%)

, GIII

G-III Apparel

$21.63 /

+0.395 (+1.86%)

, ESTC

Elastic

$61.16 /

+2.16 (+3.66%)

, CRM

Salesforce

$159.94 /

+8.22 (+5.42%)

, SNOW

Snowflake

$142.87 /

+6.255 (+4.58%)

, VSCO

Victoria's Secret

$46.00 /

+0.52 (+1.14%)

, SHLS

Shoals Technologies

$28.97 /

+1.04 (+3.72%)

Check out this evening's…

ShowHide Related Items >><<
VSCO Victoria's Secret
$46.00 /

+0.52 (+1.14%)

SPLK Splunk
$77.63 /

+1.685 (+2.22%)

SNPS Synopsys
$339.57 /

+16.07 (+4.97%)

SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

SHLS Shoals Technologies
$28.97 /

+1.04 (+3.72%)

PVH PVH Corp.
$67.30 /

+2.45 (+3.78%)

PSTG Pure Storage
$29.19 /

-0.3 (-1.02%)

OKTA Okta
$53.31 /

+2.06 (+4.02%)

GIII G-III Apparel
$21.63 /

+0.395 (+1.86%)

FIVE Five Below
$160.98 /

+3.91 (+2.49%)

ESTC Elastic
$61.16 /

+2.16 (+3.66%)

CRM Salesforce
$159.94 /

+8.22 (+5.42%)

OKTA Okta
$53.31 /

+2.06 (+4.02%)

11/29/22 Jefferies
Okta risk/reward attractive amid low expectations, says Jefferies
11/22/22 Piper Sandler
Okta price target lowered to $80 from $125 at Piper Sandler
11/14/22 Canaccord
Okta price target lowered to $70 from $85 at Canaccord
11/14/22 JMP Securities
Okta price target lowered to $105 from $145 at JMP Securities
PVH PVH Corp.
$67.30 /

+2.45 (+3.78%)

09/02/22 Deutsche Bank
PVH Corp. price target lowered to $72 from $99 at Deutsche Bank
09/02/22 Morgan Stanley
PVH Corp. price target lowered to $51 from $83 at Morgan Stanley
09/02/22 Barclays
PVH Corp. price target lowered to $60 from $87 at Barclays
08/31/22 Guggenheim
PVH Corp. price target lowered to $105 from $130 at Guggenheim
FIVE Five Below
$160.98 /

+3.91 (+2.49%)

11/28/22 Citi
Five Below price target raised to $186 from $170 at Citi
10/31/22 JPMorgan
Five Below price target raised to $184 from $159 at JPMorgan
09/01/22 Guggenheim
Five Below price target lowered to $190 from $200 at Guggenheim
09/01/22 Craig-Hallum
Five Below price target lowered to $178 from $185 at Craig-Hallum
SPLK Splunk
$77.63 /

+1.685 (+2.22%)

11/18/22 Barclays
Splunk price target lowered to $100 from $105 at Barclays
11/17/22 BofA
Splunk price target lowered to $110 from $122 at BofA
11/15/22 Mizuho
Splunk price target lowered to $100 from $110 at Mizuho
11/07/22 Wolfe Research
Splunk initiated with an Outperform at Wolfe Research
SNPS Synopsys
$339.57 /

+16.07 (+4.97%)

11/22/22 Wells Fargo
Synopsys price target lowered to $400 from $425 at Wells Fargo
11/16/22 Edward Jones
Synopsys initiated with a Hold at Edward Jones
09/29/22 Deutsche Bank
Synopsys initiated with a Buy at Deutsche Bank
09/07/22 Stifel
Stifel starts Cadence Design at Hold, prefers Synopsys on valuation basis
PSTG Pure Storage
$29.19 /

-0.3 (-1.02%)

11/25/22 JPMorgan
Pure Storage price target lowered to $40 from $43 at JPMorgan
10/31/22 Morgan Stanley
Pure Storage upgraded to Overweight from Equal Weight at Morgan Stanley
10/27/22 Wells Fargo
Meta's capex guide positive for Nvidia, AMD and others, says Wells Fargo
09/01/22 Northland
Pure Storage price target raised to $47 from $44 at Northland
GIII G-III Apparel
$21.63 /

+0.395 (+1.86%)

09/09/22 Barclays
G-III Apparel price target lowered to $18 from $22 at Barclays
09/08/22 CL King
G-III Apparel price target lowered to $26 from $45 at CL King
07/22/22 Piper Sandler
G-III Apparel assumed with an Overweight at Piper Sandler
07/21/22 KeyBanc
KeyBanc transitions coverage of Global Brands & E-Commerce with cautious view
ESTC Elastic
$61.16 /

+2.16 (+3.66%)

11/18/22 Barclays
Elastic price target lowered to $80 from $85 at Barclays
10/26/22 Truist
Elastic price target lowered to $95 from $105 at Truist
10/19/22 Baird
Elastic assumed with an Outperform at Baird
10/18/22 Barclays
Elastic price target lowered to $85 from $105 at Barclays
CRM Salesforce
$159.94 /

+8.22 (+5.42%)

11/29/22 KeyBanc
Salesforce price target lowered to $200 from $210 at KeyBanc
11/29/22 Baird
Salesforce price target lowered to $210 from $230 at Baird
11/28/22 Evercore ISI
Salesforce price target lowered to $200 from $225 at Evercore ISI
11/28/22 Stifel
Salesforce price target lowered to $185 from $200 at Stifel
SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

11/22/22 Baird
Snowflake price target lowered to $185 from $215 at Baird
11/18/22 Barclays
Snowflake price target lowered to $200 from $207 at Barclays
11/08/22 Truist
Snowflake price target lowered to $200 from $225 at Truist
11/08/22 Mizuho
Snowflake price target lowered to $185 from $225 at Mizuho
VSCO Victoria's Secret
$46.00 /

+0.52 (+1.14%)

09/16/22 JPMorgan
Victoria's Secret price target raised to $51 from $48 at JPMorgan
08/26/22 Morgan Stanley
Victoria's Secret price target lowered to $40 from $51 at Morgan Stanley
08/26/22 Barclays
Victoria's Secret price target lowered to $50 from $60 at Barclays
08/25/22 BMO Capital
Victoria's Secret price target lowered to $45 from $50 at BMO Capital
SHLS Shoals Technologies
$28.97 /

+1.04 (+3.72%)

11/16/22 Barclays
Shoals Technologies price target raised to $30 from $25 at Barclays
11/15/22 Northland
Shoals Technologies upgraded to Outperform from Market Perform at Northland
11/15/22 Piper Sandler
Shoals Technologies price target raised to $30 from $28 at Piper Sandler
11/10/22 Morgan Stanley
New California 'NEM 3.0' proposal 'screens positive,' says Morgan Stanley
VSCO Victoria's Secret
$46.00 /

+0.52 (+1.14%)

SPLK Splunk
$77.63 /

+1.685 (+2.22%)

SNPS Synopsys
$339.57 /

+16.07 (+4.97%)

SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

SHLS Shoals Technologies
$28.97 /

+1.04 (+3.72%)

PVH PVH Corp.
$67.30 /

+2.45 (+3.78%)

PSTG Pure Storage
$29.19 /

-0.3 (-1.02%)

OKTA Okta
$53.31 /

+2.06 (+4.02%)

GIII G-III Apparel
$21.63 /

+0.395 (+1.86%)

FIVE Five Below
$160.98 /

+3.91 (+2.49%)

ESTC Elastic
$61.16 /

+2.16 (+3.66%)

CRM Salesforce
$159.94 /

+8.22 (+5.42%)

  • 02
    Dec
VSCO Victoria's Secret
$46.00 /

+0.52 (+1.14%)

SPLK Splunk
$77.63 /

+1.685 (+2.22%)

SHLS Shoals Technologies
$28.97 /

+1.04 (+3.72%)

OKTA Okta
$53.31 /

+2.06 (+4.02%)

CRM Salesforce
$159.94 /

+8.22 (+5.42%)

VSCO Victoria's Secret
$46.00 /

+0.52 (+1.14%)

SPLK Splunk
$77.63 /

+1.685 (+2.22%)

SNPS Synopsys
$339.57 /

+16.07 (+4.97%)

SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

SHLS Shoals Technologies
$28.97 /

+1.04 (+3.72%)

PVH PVH Corp.
$67.30 /

+2.45 (+3.78%)

PSTG Pure Storage
$29.19 /

-0.3 (-1.02%)

OKTA Okta
$53.31 /

+2.06 (+4.02%)

GIII G-III Apparel
$21.63 /

+0.395 (+1.86%)

FIVE Five Below
$160.98 /

+3.91 (+2.49%)

ESTC Elastic
$61.16 /

+2.16 (+3.66%)

CRM Salesforce
$159.94 /

+8.22 (+5.42%)

VSCO Victoria's Secret
$46.00 /

+0.52 (+1.14%)

SPLK Splunk
$77.63 /

+1.685 (+2.22%)

SNPS Synopsys
$339.57 /

+16.07 (+4.97%)

SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

SHLS Shoals Technologies
$28.97 /

+1.04 (+3.72%)

PVH PVH Corp.
$67.30 /

+2.45 (+3.78%)

PSTG Pure Storage
$29.19 /

-0.3 (-1.02%)

OKTA Okta
$53.31 /

+2.06 (+4.02%)

FIVE Five Below
$160.98 /

+3.91 (+2.49%)

ESTC Elastic
$61.16 /

+2.16 (+3.66%)

CRM Salesforce
$159.94 /

+8.22 (+5.42%)

Hot Stocks
Snowflake CEO: Overall, things are strong » 18:45
11/30/22
11/30
18:45
11/30/22
18:45
SNOW

Snowflake

$142.87 /

+6.255 (+4.58%)

In an interview on…

In an interview on CNBC's Mad Money, Frank Slootman said for a company of Snowflake's scale to be growing at this rate is unprecedented. "The tailwinds we are experiencing in our business are enormous," he noted. "Customers are trying to accelerate and they want us to help them do it." Advertising is "red hot," and there is tremendous demand from that area, he added.

ShowHide Related Items >><<
SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

11/22/22 Baird
Snowflake price target lowered to $185 from $215 at Baird
11/18/22 Barclays
Snowflake price target lowered to $200 from $207 at Barclays
11/08/22 Truist
Snowflake price target lowered to $200 from $225 at Truist
11/08/22 Mizuho
Snowflake price target lowered to $185 from $225 at Mizuho
SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

Hot Stocks
AppLovin exec sells $17.6M in common stock » 18:33
11/30/22
11/30
18:33
11/30/22
18:33
APP

AppLovin

$14.40 /

+0.95 (+7.07%)

In a regulatory filing,…

In a regulatory filing, AppLovin disclosed that its CTO Vasily Shikin sold 1.29M shares of common stock on November 28th in a total transaction size of $17.6M.

ShowHide Related Items >><<
APP AppLovin
$14.40 /

+0.95 (+7.07%)

APP AppLovin
$14.40 /

+0.95 (+7.07%)

11/30/22 Jefferies
AppLovin initiated with a Hold at Jefferies
11/28/22 Morgan Stanley
AppLovin downgraded to Equal Weight from Overweight at Morgan Stanley
11/22/22 Citi
AppLovin price target lowered to $34 from $60 at Citi
11/17/22 JPMorgan
AppLovin reinstated with Neutral from Overweight at JPMorgan
APP AppLovin
$14.40 /

+0.95 (+7.07%)

  • 03
    Dec
APP AppLovin
$14.40 /

+0.95 (+7.07%)

APP AppLovin
$14.40 /

+0.95 (+7.07%)

APP AppLovin
$14.40 /

+0.95 (+7.07%)

Hot Stocks
Salesforce CEO: Departure of co-CEO Bret Taylor 'a gut punch' » 18:25
11/30/22
11/30
18:25
11/30/22
18:25
CRM

Salesforce

$159.94 /

+8.22 (+5.42%)

In an interview on…

In an interview on CNBC's Mad Money, Marc Benioff said, "We do our best to bring up great talent, but sometimes they have to leave." He noted that the company is seeing "unprecedented" FX headwinds that were never anticipated. Salesforce closed a lot key transactions in the quarter. "We had big wins," he added.

ShowHide Related Items >><<
CRM Salesforce
$159.94 /

+8.22 (+5.42%)

CRM Salesforce
$159.94 /

+8.22 (+5.42%)

11/29/22 KeyBanc
Salesforce price target lowered to $200 from $210 at KeyBanc
11/29/22 Baird
Salesforce price target lowered to $210 from $230 at Baird
11/28/22 Evercore ISI
Salesforce price target lowered to $200 from $225 at Evercore ISI
11/28/22 Stifel
Salesforce price target lowered to $185 from $200 at Stifel
CRM Salesforce
$159.94 /

+8.22 (+5.42%)

CRM Salesforce
$159.94 /

+8.22 (+5.42%)

CRM Salesforce
$159.94 /

+8.22 (+5.42%)

CRM Salesforce
$159.94 /

+8.22 (+5.42%)

Hot Stocks
AWS, Slalom expand next-generation strategic collaboration » 18:24
11/30/22
11/30
18:24
11/30/22
18:24
AMZN

Amazon.com

$96.50 /

+4.1 (+4.44%)

Amazon Web Services and…

Amazon Web Services and Slalom announced a multiyear extension to the companies' global Strategic Collaboration Agreement. The two companies will work together to develop vertical solutions and accelerators on AWS for customers in the energy, financial services, healthcare, life sciences, public sector, and media and entertainment industries, delivering specialized end-to-end cloud migration and modernization services to help accelerate their cloud journeys. In addition to supporting accelerated growth in Slalom markets in the U.S., the United Kingdom, Canada, Australia, Germany, Japan, and New Zealand, AWS and Slalom in 2023 will jointly create go-to-market strategies and make co-investments in support of Slalom's continued expansion into Ireland and the Netherlands, followed by additional countries in Latin America, Asia Pacific, and through Europe over the next three years. As part of the agreement, AWS and Slalom are expanding upon their 2019 announced collaboration to deliver AWS Slalom Launch Centers that help enterprises accelerate their business transformations and modernize information technology services. Launch Centers provide customers with access to the unique combination of AWS Professional Services-a global team of AWS experts who help customers reach their desired outcomes with the cloud-and Slalom's expertise in business transformation, software engineering, and analytics capabilities. Over the last three years, more than 160 customers have migrated and modernized to AWS through their work with Launch Centers.

ShowHide Related Items >><<
AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

11/30/22 JMP Securities
JMP Securities encouraged by Amazon.com's focus on innovation
11/29/22 UBS
Affirm initiated with a Neutral at UBS
11/22/22 Piper Sandler
Amazon.com price target lowered to $119 from $125 at Piper Sandler
11/21/22 JPMorgan
JPMorgan more cautious on online holiday sales, Amazon still top idea
AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

Hot Stocks
Viracta reports Phase 1b/2 trial results for Nana-val in EBV+ tumors » 18:15
11/30/22
11/30
18:15
11/30/22
18:15
VIRX

Viracta Therapeutics

$2.30 /

+0.03 (+1.32%)

Viracta Therapeutics…

Viracta Therapeutics reported preliminary dose-ranging data from the first two dose levels of the dose escalation part of the Phase 1b/2 study of Nana-val in patients with Epstein-Barr Virus-Positive - or EBV+ - recurrent/metastatic nasopharyngeal carcinoma - R/M NPC. The data are featured in an abstract accepted for a poster presentation at the European Society for Medical Oncology Immuno-Oncology Congress in Geneva, Switzerland, from December 7 - 9. The Phase 1b/2 trial's first two dose levels enrolled seven patients with EBV+ R/M NPC, six of whom were evaluable for response at the data cut-off date. Nana-val was well tolerated with no dose limiting toxicities reported. Most common Grade 1-2 AEs were fatigue, nausea, and increased creatinine. Two of six evaluable patients achieved stable disease. Plasma EBV DNA titers decreased or remained stable in both patients achieving SD, while rising in patients with progressive disease. The Phase 1b/2 trial is currently progressing through its third dose escalation cohort, with enrollment in the third dose level completed. Further safety data from the third dose level will be presented in the abstract's corresponding poster at ESMO-IO. The company anticipates initiating the Phase 2 randomized expansion portion of the Phase 1b/2 trial in the second half of 2023.

ShowHide Related Items >><<
VIRX Viracta Therapeutics
$2.30 /

+0.03 (+1.32%)

VIRX Viracta Therapeutics
$2.30 /

+0.03 (+1.32%)

01/31/22 RBC Capital
RBC Capital starts Viracta Therapeutics at Outperform, sees 'overlooked' story
01/31/22 RBC Capital
Viracta Therapeutics initiated with an Outperform at RBC Capital
Hot Stocks
Musk says Apple CEO never considered removing Twitter from App Store » 18:10
11/30/22
11/30
18:10
11/30/22
18:10
AAPL

Apple

$148.00 /

+6.81 (+4.82%)

, TWTR

Twitter

$53.71 /

+ (+0.00%)

Elon Musk tweeted that he…

Elon Musk tweeted that he had a "good conversation" with Apple (AAPL) CEO Tim Cook, saying the two "resolved the misunderstanding about Twitter (TWTR) potentially being removed from the App Store." "Tim was clear that Apple never considered doing so," Musk added. Reference Link

ShowHide Related Items >><<
TWTR Twitter
$53.71 /

+ (+0.00%)

AAPL Apple
$148.00 /

+6.81 (+4.82%)

AAPL Apple
$148.00 /

+6.81 (+4.82%)

11/30/22 Wedbush
China lockdown ends in iPhone city, heavy lifting ahead for Apple, says Wedbush
11/30/22 Baird
Apple estimates lowered due to ongoing assembly challenges, says Baird
11/29/22 Deutsche Bank
Apple Pay taking e-commerce share from PayPal, says Deutsche Bank
11/28/22 Wedbush
Apple iPhone shortages build into holiday season, says Wedbush
TWTR Twitter
$53.71 /

+ (+0.00%)

11/23/22 Morgan Stanley
Morgan Stanley wonders if 'value opportunity emerging' in Tesla after selloff
10/31/22 Gordon Haskett
Gordon Haskett wonders if 'more going on' as Fertitta takes stake in Wynn
10/21/22 Wedbush
Twitter deal still 'brutal situation' for Tesla holders, Wedbush says
10/18/22 Gordon Haskett
Bilson sees Tesla share sale coming with Musk $8B short for Twitter
TWTR Twitter
$53.71 /

+ (+0.00%)

AAPL Apple
$148.00 /

+6.81 (+4.82%)

TWTR Twitter
$53.71 /

+ (+0.00%)

AAPL Apple
$148.00 /

+6.81 (+4.82%)

TWTR Twitter
$53.71 /

+ (+0.00%)

AAPL Apple
$148.00 /

+6.81 (+4.82%)

TWTR Twitter
$53.71 /

+ (+0.00%)

AAPL Apple
$148.00 /

+6.81 (+4.82%)

Hot Stocks
OncoCyte CEO Ronnie Andrews to step down, Joshua Riggs named interim CEO » 18:01
11/30/22
11/30
18:01
11/30/22
18:01
OCX

OncoCyte

/

+

Oncocyte announced that…

Oncocyte announced that Ronnie Andrews will step down from his role as CEO and as a director of the company's board of directors effective December 1. In order to ensure a smooth transition effective as of December 2, Joshua Riggs will serve as interim CEO until such time as a new CEO has been identified and retained and Andrews will continue to act a consultant until February 28, 2023. Riggs, who has been Oncocyte's General Manager, Transplant since July 2022 and was the company's Senior Director Business Development from August 2020 until September 2022, is a seasoned business development strategist with significant experience working with early and growth-stage molecular diagnostics companies. From January 2016 to July 2020, he was a principal at Bethesda Group, LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms to market.

ShowHide Related Items >><<
OCX OncoCyte
/

+

OCX OncoCyte
/

+

11/17/22 Piper Sandler
OncoCyte downgraded to Neutral at Piper with revenue ramp slowing
11/17/22 Piper Sandler
OncoCyte downgraded to Neutral from Overweight at Piper Sandler
11/14/22 Piper Sandler
OncoCyte price target lowered to $1 from $1.50 at Piper Sandler
08/17/22 Piper Sandler
OncoCyte price target raised to $1.50 from $1.40 at Piper Sandler
OCX OncoCyte
/

+

  • 14
    Apr
Hot Stocks
Eli Lilly says donanemab met all primary, secondary endpoints in Phase 3 study » 18:01
11/30/22
11/30
18:01
11/30/22
18:01
LLY

Eli Lilly

$371.00 /

+7.075 (+1.94%)

Eli Lilly and Company…

Eli Lilly and Company announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in the Phase 3 TRAILBLAZER-ALZ 4 study, providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic Alzheimer's disease treated with amyloid-targeting therapies. These data comparing donanemab to Aduhelm to assess superiority on amyloid plaque reduction were shared at the 15th Clinical Trials on Alzheimer's Disease conference. Donanemab is an investigational antibody that targets a modified form of beta amyloid plaque called N3pG. Through the FDA's accelerated approval pathway, the FDA has recognized that the reduction of amyloid beta plaque is a biomarker reasonably likely to predict clinical benefit in the treatment of early Alzheimer's disease. Through the FDA's accelerated approval pathway, the FDA has recognized that the reduction of amyloid beta plaque is a biomarker reasonably likely to predict clinical benefit in the treatment of early Alzheimer's disease. "The purpose of this first ever active comparator trial of amyloid lowering agents was to answer important questions about potential differences in amyloid plaque reduction," said Mark Mintun, M.D., group vice president of pain and neurodegeneration research and development, Eli Lilly and Company. "These data reinforce our confidence in donanemab's unique mechanism of action based on reductions in key biomarkers of Alzheimer's disease, amyloid plaque and plasma phosphorylated tau (P-tau). Importantly, this was also the first study to obtain ARIA rates side by side using identical methods for ARIA assessment in the same patient population, demonstrating the ability to disconnect rate of plaque clearance from rate of ARIA incidence."

ShowHide Related Items >><<
LLY Eli Lilly
$371.00 /

+7.075 (+1.94%)

LLY Eli Lilly
$371.00 /

+7.075 (+1.94%)

11/30/22 Piper Sandler
Bebtelovimab losing EUA has 'limited impact' on Piper model for AbCellera
11/30/22 JPMorgan
Biogen Alzheimer's data increases approval confidence, says JPMorgan
11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
11/22/22 Berenberg
Eli Lilly price target raised to $375 from $345 at Berenberg
LLY Eli Lilly
$371.00 /

+7.075 (+1.94%)

LLY Eli Lilly
$371.00 /

+7.075 (+1.94%)

LLY Eli Lilly
$371.00 /

+7.075 (+1.94%)

LLY Eli Lilly
$371.00 /

+7.075 (+1.94%)

Syndicate
Intellia Therapeutics $250M Spot Secondary; price range $45.80-$47.80 » 17:50
11/30/22
11/30
17:50
11/30/22
17:50
NTLA

Intellia Therapeutics

$51.41 /

+3.44 (+7.17%)

Goldman Sachs & Co.…

Goldman Sachs & Co. is acting as the sole underwriter for the proposed offering.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

11/14/22 Chardan
Intellia Therapeutics price target raised to $129 from $121 at Chardan
11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

  • 01
    Dec
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

Syndicate
Freyr Battery 13.5M share Spot Secondary; price range $11.25-$11.75 » 17:41
11/30/22
11/30
17:41
11/30/22
17:41
FREY

Freyr Battery

$13.65 /

+0.505 (+3.84%)

Credit Suisse, BofA and…

Credit Suisse, BofA and Morgan Stanley are acting as joint book running managers for the offering.

ShowHide Related Items >><<
FREY Freyr Battery
$13.65 /

+0.505 (+3.84%)

FREY Freyr Battery
$13.65 /

+0.505 (+3.84%)

10/31/22 Cowen
Cowen starts Freyr Battery at Outperform, sees 'less technology risk'
10/31/22 Cowen
Freyr Battery initiated with an Outperform at Cowen
09/21/22 Morgan Stanley
Freyr Battery price target raised to $26, named a 'Top Pick' at Morgan Stanley
09/01/22 BTIG
Freyr Battery price target raised to $25 from $20 at BTIG
FREY Freyr Battery
$13.65 /

+0.505 (+3.84%)

  • 01
    Dec
FREY Freyr Battery
$13.65 /

+0.505 (+3.84%)

FREY Freyr Battery
$13.65 /

+0.505 (+3.84%)

Periodicals
Warner Bros., Amazon partnering to produce animated DC projects, Verge says » 17:36
11/30/22
11/30
17:36
11/30/22
17:36
WBD

Warner Bros. Discovery

$11.41 /

+0.265 (+2.38%)

, AMZN

Amazon.com

$96.50 /

+4.1 (+4.44%)

Warner Bros. Discovery…

Warner Bros. Discovery (WBD) and Amazon (AMZN) are partnering to produce new animated projects based on DC Comics' characters and stories, The Verge's Charles Pulliam-Moore reports. "David Zaslav has been much more open to exploring all of our animated IP and being able to do it on different platforms," Warner Bros. Television Studios chairwoman Channing Dungey said during During a keynote session at C21Media's annual Content London event this week. "Certainly, HBO Max is going to be our first stop, but we're already in the process of closing a big deal with Amazon that's going to feature some of our DC-branded content in animation." Reference Link

ShowHide Related Items >><<
WBD Warner Bros. Discovery
$11.41 /

+0.265 (+2.38%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

WBD Warner Bros. Discovery
$11.41 /

+0.265 (+2.38%)

11/14/22 Spin-Off Research
Warner Bros. Discovery downgraded to Hold from Buy at Spin-Off Research
11/10/22 Citi
Warner Bros. Discovery price target lowered to $18 from $21 at Citi
11/08/22 Deutsche Bank
Warner Bros. Discovery price target lowered to $35 from $48 at Deutsche Bank
11/07/22 RBC Capital
Warner Bros. Discovery price target lowered to $27 from $44 at RBC Capital
AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

11/30/22 JMP Securities
JMP Securities encouraged by Amazon.com's focus on innovation
11/29/22 UBS
Affirm initiated with a Neutral at UBS
11/22/22 Piper Sandler
Amazon.com price target lowered to $119 from $125 at Piper Sandler
11/21/22 JPMorgan
JPMorgan more cautious on online holiday sales, Amazon still top idea
WBD Warner Bros. Discovery
$11.41 /

+0.265 (+2.38%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

WBD Warner Bros. Discovery
$11.41 /

+0.265 (+2.38%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

WBD Warner Bros. Discovery
$11.41 /

+0.265 (+2.38%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

WBD Warner Bros. Discovery
$11.41 /

+0.265 (+2.38%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

Hot Stocks
Shoals Technologies falls 9% to $26.24 after 20M share Class A stock offering  17:34
11/30/22
11/30
17:34
11/30/22
17:34
SHLS

Shoals Technologies

$28.97 /

+1.04 (+3.72%)

 
ShowHide Related Items >><<
SHLS Shoals Technologies
$28.97 /

+1.04 (+3.72%)

SHLS Shoals Technologies
$28.97 /

+1.04 (+3.72%)

11/16/22 Barclays
Shoals Technologies price target raised to $30 from $25 at Barclays
11/15/22 Northland
Shoals Technologies upgraded to Outperform from Market Perform at Northland
11/15/22 Piper Sandler
Shoals Technologies price target raised to $30 from $28 at Piper Sandler
11/10/22 Morgan Stanley
New California 'NEM 3.0' proposal 'screens positive,' says Morgan Stanley
SHLS Shoals Technologies
$28.97 /

+1.04 (+3.72%)

SHLS Shoals Technologies
$28.97 /

+1.04 (+3.72%)

SHLS Shoals Technologies
$28.97 /

+1.04 (+3.72%)

SHLS Shoals Technologies
$28.97 /

+1.04 (+3.72%)

Hot Stocks
Orthofix confirms $23.00 per share cash buyout offer from PE funds » 17:32
11/30/22
11/30
17:32
11/30/22
17:32
OFIX

Orthofix

$17.97 /

+0.59 (+3.39%)

, SPNE

SeaSpine

$7.48 /

+0.25 (+3.46%)

In a regulatory filing,…

In a regulatory filing, Orthofix Medical (OFIX) announced that it received an unsolicited, non-binding indication of interest from two private equity fund sponsors to acquire all of the outstanding equity of Orthofix for $23.00 per share in cash. The non-binding indication of interest was subject to, among other things, the completion of due diligence, to the sole satisfaction of the sponsors, the arranging of debt financing to fund the purchase price, the completion of unspecified regulatory approvals, and internal approvals by the investment committees of the sponsors. As previously announced, Orthofix has entered into a definitive merger agreement with SeaSpine Holdings (SPNE) to combine in an all-stock transaction, pursuant to which, at the close of the transaction, Orthofix stockholders will own approximately 56.5% of the combined business, and SeaSpine stockholders will own approximately 43.5% of the combined business. The transaction is expected to close early in the first quarter of 2023, subject to Orthofix and SeaSpine stockholder approvals and other customary closing conditions. The Orthofix board engaged in a comprehensive and thorough review and evaluation of the indication of interest Orthofix received, in consultation with legal and financial advisers. Following such review and evaluation, the Orthofix board unanimously determined that the SeaSpine merger transaction continues to be in the best interests of Orthofix and its stockholders. The Orthofix board further unanimously determined that it is unable to conclude that the indication of interest is reasonably likely to lead to a superior proposal under the terms of Orthofix's merger agreement with SeaSpine. The Orthofix board reaffirms to stockholders its recommendation in favor of the SeaSpine merger transaction and remains fully committed to completing the transaction with SeaSpine. A special meeting of Orthofix stockholders has been scheduled for January 4, 2023 to vote on a proposal to approve the issuance of Orthofix common stock in the proposed SeaSpine merger transaction.

ShowHide Related Items >><<
SPNE SeaSpine
$7.48 /

+0.25 (+3.46%)

OFIX Orthofix
$17.97 /

+0.59 (+3.39%)

OFIX Orthofix
$17.97 /

+0.59 (+3.39%)

06/28/22 Stifel
Stifel cuts Orthofix target, says momentum 'faded' during Q2
04/19/22 Stifel
J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
03/04/22 Stifel
Orthofix upgraded to Buy from Hold at Stifel
SPNE SeaSpine
$7.48 /

+0.25 (+3.46%)

11/02/22 Truist
SeaSpine downgraded to Hold from Buy at Truist
10/12/22 Piper Sandler
CMS proposal a positive for Med Tech sector, says Piper Sandler
08/03/22 Piper Sandler
SeaSpine price target lowered to $12 from $21 at Piper Sandler
07/20/22 Truist
SeaSpine price target lowered to $12 from $20 at Truist
SPNE SeaSpine
$7.48 /

+0.25 (+3.46%)

OFIX Orthofix
$17.97 /

+0.59 (+3.39%)

OFIX Orthofix
$17.97 /

+0.59 (+3.39%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.